Britain and America have forged a landmark commercial pact that will guarantee zero levies on British medicine exports going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost expenditure on medicines through the National Health Service (NHS). This commitment ensures that duties on these key products will stay at zero for a duration of three years.
This agreement is in response to previous statements to hike import taxes on patented drug products, with increases floated as high as 100%.
"This deal with the United Kingdom reinforces the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Trade Importance
Drugs constitute one of the the United Kingdom's most significant goods shipped to the US, which is easily the largest destination for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months prior to the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This guarantee protects employment, stimulates investment and sets the stage for the UK to emerge as a global hub for life sciences," a government official stated.
Key UK Commitments
The deal entails several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase overall NHS spending on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. In the past, refunds were more than 20%.
Recent Tensions
This agreement follows a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were exacerbated by arguments that American patients were paying a premium for the same drugs than people in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or abandoned, while major investments have been pledged toward American operations.
The Science Minister publicly accepted that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
